Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immuneering Corporation stock logo
IMRX
Immuneering
$4.13
-4.0%
$2.58
$1.00
$4.60
$148.62M0.382.59 million shs317,161 shs
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.92
+8.5%
$1.96
$1.29
$3.51
$176.98M0.21187,954 shs17,431 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.97
-2.6%
$12.75
$6.43
$27.38
$163.27M0.43159,496 shs91,806 shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$0.81
+8.6%
$0.97
$0.69
$4.61
$38.76M1.63325,486 shs129,344 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immuneering Corporation stock logo
IMRX
Immuneering
0.00%-6.56%+49.10%+225.20%+252.99%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
0.00%+10.14%+1.05%-2.54%-12.73%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+7.99%+2.69%-3.43%+102.34%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
0.00%-0.77%-16.95%+4.64%-82.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Immuneering Corporation stock logo
IMRX
Immuneering
3.239 of 5 stars
3.32.00.00.02.55.00.6
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
1.8724 of 5 stars
3.83.00.00.00.01.70.0
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.3065 of 5 stars
3.50.01.72.73.82.51.3
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
3.6913 of 5 stars
3.45.00.00.03.21.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immuneering Corporation stock logo
IMRX
Immuneering
2.60
Moderate Buy$13.25220.82% Upside
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
3.50
Strong Buy$11.00472.92% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50135.16% Upside
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.83
Moderate Buy$7.50826.84% Upside

Current Analyst Ratings Breakdown

Latest STTK, IPHA, LFVN, and IMRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/5/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
5/7/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.00
5/6/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/24/2025
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.50 ➝ $11.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immuneering Corporation stock logo
IMRX
Immuneering
$320K464.50N/AN/A$1.33 per share3.11
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$12.62M14.02N/AN/A$0.11 per share17.45
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.82$0.88 per share14.71$2.05 per share6.33
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$4.61M8.42N/AN/A$1.67 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immuneering Corporation stock logo
IMRX
Immuneering
-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
-$53.53MN/A0.00N/AN/AN/AN/A9/17/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.80N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$75.41M-$1.39N/AN/AN/AN/A-79.69%-69.13%7/30/2025 (Estimated)

Latest STTK, IPHA, LFVN, and IMRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.25N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.40N/AN/AN/AN/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/5/2025Q1 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.41-$0.42-$0.01-$0.42N/AN/A
5/1/2025Q1 2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.29-$0.27+$0.02-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.39%N/A26.09%3 Years
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/AN/AN/AN/AN/A

Latest STTK, IPHA, LFVN, and IMRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
7.48
7.48
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
2.52
2.60
2.60
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/A
9.08
9.08

Institutional Ownership

CompanyInstitutional Ownership
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
0.16%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
58.74%

Insider Ownership

CompanyInsider Ownership
Immuneering Corporation stock logo
IMRX
Immuneering
22.90%
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
31.89%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
12.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immuneering Corporation stock logo
IMRX
Immuneering
6035.99 million27.75 millionNot Optionable
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
22092.18 million62.78 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10047.90 million42.16 millionOptionable

Recent News About These Companies

Shattuck Labs (NASDAQ:STTK) Shares Down 2% - Here's What Happened
Shattuck Labs, Inc. (STTK) - Yahoo Finance
Shattuck Labs Full Year 2024 Earnings: Misses Expectations
Shattuck Labs reports Q4 EPS (37c), consensus (32c)
H.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)
Shattuck Labs initiated with an Outperform at Leerink
H.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)
Shattuck Labs’ SL-325 shows positive results in inflammatory bowel disease

New MarketBeat Followers Over Time

Media Sentiment Over Time

Immuneering stock logo

Immuneering NASDAQ:IMRX

$4.13 -0.17 (-3.95%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.15 +0.02 (+0.51%)
As of 07/18/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Innate Pharma stock logo

Innate Pharma NASDAQ:IPHA

$1.94 +0.16 (+9.30%)
As of 07/18/2025 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.97 -0.34 (-2.55%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$12.96 -0.01 (-0.04%)
As of 07/18/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Shattuck Labs stock logo

Shattuck Labs NASDAQ:STTK

$0.81 +0.06 (+8.62%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.80 -0.01 (-1.14%)
As of 07/18/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.